Eisai Newswire

Eisai Newswire

Comprehensive Real-Time News Feed for Eisai.

Results 1 - 20 of 48 in Eisai

  1. Eisai Inc. Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study Will...Read the original story

    Tuesday Jun 20 | BioSpace

    Eisai Inc. Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study Will Continue As Planned Based On Interim Safety Analysis By Independent Data Monitoring Committee /PRNewswire/ -- Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin will continue as planned, based on the recommendation of an independent Data Monitoring Committee after it completed a pre-specified interim safety analysis evaluating the incidence of MACE events, defined as cardiovascular death, myocardial infarction or stroke. The DMC will continue to monitor the ongoing safety of lorcaserin as planned.

    Comment?

  2. Dova Pharmaceuticals (DOVA) to Raise $66 Million in IPORead the original story w/Photo

    Tuesday Jun 20 | AmericanBankingNews.com

    ... a disorder characterized by a low blood platelet count. Our drug candidate, avatrombopag, which we acquired from Eisai, Inc., or Eisai, in March 2016, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that we are developing for ...

    Comment?

  3. Arena Announces Shareholders And Board Of Directors Approve Reverse Stock SplitRead the original story

    Wednesday Jun 14 | BioSpace

    ... pain associated with Crohn's disease. In addition, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International ...

    Comment?

  4. Eisai Inc. Release: Lenvatinib Demonstrates Positive Results Vs...Read the original story

    Sunday Jun 4 | BioSpace

    Eisai Inc. Release: Lenvatinib Demonstrates Positive Results Vs Sorafenib Across All Endpoints In First-Line Phase III Non-Inferiority Trial Of Unresectable Hepatocellular Carcinoma /PRNewswire/ -- Eisai Inc. today announced results from the REFLECT study , a Phase 3 trial evaluating lenvatinib , the company's multiple receptor tyrosine kinase inhibitor , for the first-line treatment of patients with unresectable hepatocellular carcinoma .

    Comment?

  5. Arena Solutions Provides Corporate Update And Reports First Quarter 2017 Financial ResultsRead the original story

    May 9, 2017 | BioSpace

    ... associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH ...

    Comment?

  6. Hear from Top US and International Biologics Experts at ACI's 8th Annual Summit on BiosimilarsRead the original story w/Photo

    May 8, 2017 | PR Log

    ... such as Amgen, Association for Accessible Medicines, BIO, Biogen Inc., Boehringer Ingelheim, Coherus Biosciences Inc., Eisai Inc., Endo Pharmaceuticals Inc., Momenta Pharmaceuticals, National Council for Prescription Drug Programs, Novo Nordisk, ...

    Comment?

  7. Arena To Release First Quarter 2017 Financial Results And Provide...Read the original story

    May 1, 2017 | BioSpace

    ... associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH ...

    Comment?

  8. H3 Biomedicine Appoints Ph.D., To Chief Data Sciences OfficerRead the original story

    Apr 30, 2017 | BioSpace

    H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai's global Oncology Business Group, announced today that Lihua Yu, Ph.D., has been promoted to Chief Data Sciences Officer . Dr. Yu previously served as H3 Biomedicine's Vice President, Data Science and Information Technology.

    Comment?

  9. Eisai Inc. Release: Meta-Analysis Of Published Trials Supports The...Read the original story

    Apr 26, 2017 | BioSpace

    Eisai Inc. Release: Meta-Analysis Of Published Trials Supports The Extrapolation Of Antiepileptic Drug Efficacy Data From Adult To Pediatric Patients With Primary Generalized Tonic-Clonic Seizures /PRNewswire/ -- Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug treatment versus placebo on primary generalized tonic-clonic seizures appears similar between adults and children living with epilepsy. The results were presented at the American Academy of Neurology Annual Meeting in , and were selected by AAN to be included in a "Best Of" epilepsy session.

    Comment?

  10. Eisai Inc. Announces Continued Support Of Initiatives For The Elimination Of Lymphatic FilariasisRead the original story

    Apr 18, 2017 | BioSpace

    This announcement was made at an event held in Under the London Declaration, Eisai signed an agreement with the World Health Organization to supply 2.2 billion high-quality diethylcarbamazine tablets for the treatment of LF, which were running in short supply worldwide, at Price Zero by the year 2020. As of the end of , have been supplied to 27 countries.

    Comment?

  11. Bio-Path Holdings, Inc. Announces Appointment Of As Vice President Of Clinical DevelopmentRead the original story

    Apr 16, 2017 | BioSpace

    ... and medical positions of increasing responsibility at Glaxo Inc., Marion Merrell Dow, Hoechst Marion Rousel, and Eisai, Inc. Dr. Hahne earned his BA in chemistry from Grinnell College and his MD from Cornell University. He conducted his residency in ...

    Comment?

  12. Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice...Read the original story

    Apr 17, 2017 | World News Report

    ... and medical positions of increasing responsibility at Glaxo Inc., Marion Merrell Dow, Hoechst Marion Rousel, and Eisai, Inc. Dr. Hahne earned his BA in chemistry from Grinnell College and his MD from Cornell University. He conducted his residency in ...

    Comment?

  13. Collaborations speed putting new therapeutic drugs on marketRead the original story

    Apr 10, 2017 | NewsOK.com

    ... Forum hosted by Oklahoma Medical Research Foundation. He moderated a panel composed of human geneticist Janna Hutz, of Eisai Inc. north of Boston; Pfizer geneticist Hakan Sakul, of San Diego; biophysicist Anil Naboodiripad, of Dr. Reddy's Labs of ...

    Comment?

  14. Morphotek Launches ADC Services BusinessRead the original story w/Photo

    Apr 3, 2017 | Contract Pharma Breaking News

    Morphotek, Inc ., a subsidiary of Eisai Inc., has launched its Antibody Drug Conjugate Services business based on its REsidue-SPEcific Conjugation Technology and eribulin-linker toxin platforms. RESPECT is a site-specific conjugation technology that targets select amino acid residues as a way of producing investigational homogeneous ADCs with defined drug-to-antibody ratios.

    Comment?

  15. Morphotek And Launch Educational Resource On Clinical TrialsRead the original story w/Photo

    Mar 21, 2017 | BioSpace

    /PRNewswire/ -- Morphotek , Inc., a subsidiary of Eisai Inc., and the Sandy Rollman Ovarian Cancer Foundation (SROCF) announced today the launch of a resource to educate ovarian cancer patients and caregivers on clinical trials. Morphotek and SROCF ...

    Comment?

  16. Available Now: New Toolkit Encourages Better Communication to Help...Read the original story

    Mar 21, 2017 | Newswise

    Chicago, IL : - The Hematology/Oncology Pharmacy Association , in partnership with Eisai Inc. and Helsinn Therapeutics , Inc., today announced the launch of the Time to Talk CINV a toolkit, which is comprised of resources for patients with cancer going through chemotherapy and their healthcare providers. The tools, which were created with guidance from patients, caregivers, pharmacists and nurses, encourage open, two-way communication between patients and their healthcare team to ensure no patient is needlessly suffering from chemotherapy-induced nausea and vomiting .

    Comment?

  17. Arena Provides Corporate Update And Reports Fourth Quarter And Full-Year 2016 Financial ResultsRead the original story

    Mar 14, 2017 | BioSpace

    In the last nine months since the arrival of the new management team, we prioritized our Phase 2 programs; strengthened our board and team to support our strategy; implemented cost reduction measures; renegotiated our agreement with Eisai; and took a methodical approach to maximizing the value of our assets," said "This year we expect to report results from all three of our proprietary Phase 2 programs, beginning with ralinepag in mid-year for pulmonary arterial hypertension," Mr. Munshi stated. "For etrasimod, we remain focused on maximizing the broad clinical utility of this compound in a time and cost effective manner.

    Comment?

  18. H3 Biomedicine to Present New Data from Recent Research Advancements...Read the original story

    Mar 9, 2017 | Customer Interaction Solutions

    H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai's global Oncology Business Group, announced today that company scientists will present one oral and five poster presentations at the 2017 American Association of Cancer Research Annual Meeting in Washington, D.C., which is being held from April 1-5, 2017. Presentations will include first disclosures and updates on H3's lead programs in clinical development; H3B-6454, H3B-8800 and H3B-6527.

    Comment?

  19. Arena To Provide Corporate Update And Release Fourth Quarter And...Read the original story

    Mar 6, 2017 | BioSpace

    ... associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH ...

    Comment?

  20. Arena Pharmaceuticals to Provide Corporate Update and Release Fourth...Read the original story

    Mar 6, 2017 | Customer Interaction Solutions

    ... associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH ...

    Comment?